Embody GLP-1

Product Details

What Is Embody GLP-1?

Embody GLP-1 is a recurring telehealth program that connects eligible adults with independent licensed clinicians for medical weight-management evaluation. When clinically appropriate, a provider may prescribe compounded semaglutide or compounded tirzepatide, generally supplied as a once-weekly subcutaneous injection.

The program may include virtual consultations, medication, patient-portal access, nursing support, and home delivery. Embody operates the technology and administrative platform but does not independently diagnose patients, practice medicine, manufacture medication, or operate as the dispensing pharmacy.

Who May Consider Embody GLP-1?

Adults seeking professional help with weight management may consider the program after completing its eligibility assessment. It may suit self-pay patients who prefer online medical review, prescription delivery, recurring support, and no routine in-person clinic visits.

Enrollment does not guarantee that medication will be prescribed. A licensed clinician reviews the patient’s health history and decides whether GLP-1 treatment is medically appropriate. People with unexplained weight changes or ongoing symptoms should seek proper medical evaluation.

How May Embody GLP-1 Support Weight Management?

GLP-1 medicines influence pathways involved in appetite, satiety, glucose regulation, and gastric emptying. Tirzepatide acts on both GIP and GLP-1 receptors, while semaglutide acts primarily on GLP-1 receptors.

For eligible patients, these effects may support lower food intake when treatment is combined with appropriate nutrition, physical activity, and ongoing clinical guidance. The prescribing provider determines whether potential benefits outweigh individual risks.

Results vary based on medication, dose, adherence, starting health, diet, activity, and other factors. Compounded medication should not be presented as equivalent to an FDA-approved branded product.

Medication Options

Current official program materials display two principal compounded injectable options. Exact formulation, concentration, quantity, and dosing instructions depend on the prescription and dispensing pharmacy.

• Compounded Semaglutide

Semaglutide is a GLP-1 receptor agonist that can reduce appetite and slow gastric emptying. Compounded semaglutide is prescribed only after clinician review and is not FDA approved.

• Compounded Tirzepatide

Tirzepatide activates GIP and GLP-1 receptors and may reduce appetite. Compounded tirzepatide is individually prescribed, prepared by a partner pharmacy, and is not FDA approved.

FDA-Approved Branded Medication

A clinician may alternatively prescribe an FDA-approved branded medication when medically appropriate. Embody states that it does not sell, dispense, ship, or include the cost of branded prescriptions in its compounded-medication program.

Prescription and Dosage Information

Potential Benefits

• May support appetite management when prescribed for an eligible patient.
• Designed to support medically supervised weight management alongside lifestyle changes.
• Provides access to licensed clinicians for evaluation and prescription decisions.
• Includes ongoing support and refill review through the patient portal.
• May improve treatment convenience through weekly dosing and home delivery.

These are potential program and medication benefits rather than guaranteed outcomes. Individual responses and tolerability differ considerably.

Important Limitations

• Medication is available only after clinician approval.
• Compounded semaglutide and tirzepatide are not FDA approved.
• Exact formulation may differ between dispensing pharmacies.
• Weight-loss outcomes are not guaranteed.
• Recurring billing continues until properly cancelled.
• Discounted plans may require a three-, six-, or twelve-month commitment.
• Prescription products generally cannot be refunded after being ordered.
• Service is not currently advertised as available in Louisiana.
• The program does not replace emergency or in-person medical care.

FDA does not verify the safety, effectiveness, quality, or consistency of compounded drugs before marketing. FDA has also raised concerns about dosing errors, fraudulent labels, unapproved ingredients, and quality issues involving compounded GLP-1 products.

How To Use?

• Complete the online health assessment accurately.
• Submit the required medical history and patient intake information.
• Use the medication only after approval by a licensed prescriber.
• Inject the prescribed dose once weekly when instructed.
• Follow the pharmacy label for syringe measurement, injection technique, and storage.
• Do not raise, lower, divide, or repeat a dose without provider approval.
• Request refills and report side effects through the patient portal.
• Do not share medication, needles, or injection supplies with another person.

The prescribed dose and concentration can differ from those used by another patient, even when the medication name appears the same.

Warnings And Precautions

• Do not use semaglutide or tirzepatide with a personal or family history of medullary thyroid carcinoma or with MEN 2.
• Do not use during pregnancy; discuss plans for pregnancy with the prescribing provider.
• Breastfeeding patients should obtain specific medical guidance.
• Tell the provider about previous pancreatitis, gallbladder problems, kidney disease, severe digestive disease, or diabetic retinopathy.
• Report severe or persistent abdominal pain, especially when accompanied by vomiting.
• Severe nausea, vomiting, or diarrhea may cause dehydration and worsen kidney function.
• Insulin and sulfonylureas may increase the risk of low blood sugar when combined with treatment.
• GLP-1 medicines delay gastric emptying and may affect absorption of oral medication.
• Seek immediate help for facial swelling, breathing difficulty, severe rash, fainting, or another serious allergic reaction.
• Report new vision changes, jaundice, severe stomach symptoms, or significant mood changes promptly.

Patients should provide the prescriber with a complete list of medicines, supplements, medical conditions, allergies, and planned procedures before treatment begins.

Possible Side Effects And Interactions

Common effects may include nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, reduced appetite, fatigue, bloating, belching, headache, and injection-site reactions. Symptoms can vary by medication, dose, formulation, and patient.

Serious risks may include pancreatitis, gallbladder problems, kidney injury from dehydration, severe allergic reactions, vision changes, hypoglycemia with certain diabetes medicines, and possible thyroid C-cell tumors. GLP-1 medicines may also alter oral medication absorption by delaying stomach emptying.

Pharmacy And Quality Information

Embody states that compounded prescriptions are dispensed through US-based 503A compounding pharmacies after a licensed provider issues an individualized prescription. The platform lists several possible pharmacy partners, including Red Rock Pharmacy, Health Warehouse, Precision Compounding Pharmacy, and Triad Rx.

Pros

• Fully online eligibility and medical-review process
• Licensed-provider prescription decision
• Semaglutide and tirzepatide options
• Medication and support may be bundled
• Free expedited delivery advertised
• Month-to-month option available
• Lower rates offered with longer commitments
• Full refund if the provider medically disqualifies the applicant before medication is dispensed

Cons

• Recurring billing applies.
• Discounted plans require commitments.
• Exact formulation and pharmacy may vary.
• Prescription products cannot usually be refunded after ordering.
• Promotional and legal pages display different pricing and guarantee language.
• Consult fees may remain non-refundable.

Pricing And Subscription Terms

The official Terms updated July 1, 2026 list recurring monthly and commitment-based prices for compounded injectable programs.

• Semaglutide pricing starts at: $69 per month
• Tirzepatide pricing starts at: $119 per month

What May Be Included

Depending on the selected program and clinical eligibility, the subscription price may include:

• Provider consultation and chart review
• Prescribed compounded medication
• Online patient support
• Nursing access
• Patient-portal services
• Prescription refill review
• Medication shipping
• Certain laboratory or related services

The refund policy notes that included consultations, medications, laboratory services, and support may differ between programs. Final charges may also vary according to medication and pharmacy selection.

Subscription And Cancellation

Subscriptions renew automatically until cancelled. Commitment-based discounts require the customer to remain responsible for the current selected term, and unused portions are generally non-refundable.

One official policy requires cancellation at least 72 hours before billing, while the current Terms require notice at least five days before the end of the prescription period. Submitting cancellation at least five days before renewal provides the safer deadline.

Pharmacist Note

Confirm the medication name, concentration, prescribed dose, syringe units, storage conditions, and dispensing pharmacy before the first injection. Never copy another patient’s dose. Contact the provider or pharmacist when instructions are unclear, the medication looks unusual, or significant side effects develop.

FAQ

1. What type of product is Embody GLP-1?

Embody GLP-1 is an online medical weight-management program. It connects eligible adults with licensed clinicians who may prescribe compounded semaglutide or tirzepatide after completing an individualized medical assessment.

2. How is the medication taken?

Currently promoted compounded options are generally injected under the skin once weekly. The exact concentration, syringe measurement, dose, titration plan, and injection instructions are determined by the provider and pharmacy.

3. Does everyone qualify for treatment?

No. Completing the assessment or making an initial payment does not guarantee approval. A licensed provider reviews the medical intake and may decide that GLP-1 treatment is inappropriate.

4. Are Embody compounded medications FDA approved?

No. Compounded semaglutide and compounded tirzepatide are not FDA approved. FDA does not review compounded products for safety, effectiveness, manufacturing quality, or consistency before they are marketed.

5. What does the monthly price include?

The subscription may include provider evaluation, compounded medication when prescribed, ongoing support, portal access, and shipping. Included services can vary depending on the selected plan and clinical requirements.

6. Can the subscription be cancelled?

Month-to-month plans may be cancelled, but notice must be submitted before the renewal deadline. Discounted three-, six-, and twelve-month plans involve commitment terms and generally do not refund unused portions.

Medical Disclaimer

Embody GLP-1 is a telehealth service involving prescription medication, not a dietary supplement. Eligibility, medication selection, dosage, and ongoing treatment must be determined by a licensed healthcare provider.

Compounded semaglutide and tirzepatide are not FDA approved. They have not undergone FDA premarket review for safety, effectiveness, manufacturing quality, or labeling. This information does not replace the prescribing provider’s instructions, the dispensing pharmacy label, or emergency medical care.

Sources And Product Review Information

• Official Website: Embody GLP 1
• Official Embody medication safety information.
• Official Embody Terms and current pricing programs.
• Official Embody cancellation and refund policy.